Tags

Type your tag names separated by a space and hit enter

The tramadol option.
Eur J Pain. 2000; 4 Suppl A:15-21.EJ

Abstract

Tramadol is an option for the treatment of rheumatological pain. Its mode of action and safety profile distinguishes it from other opioids. Tramadol differs from other opioids by combining a weak opioid and a monoaminergic mode of action. It is effective in different types of moderate-to-severe pain, including neuropathic pain. Moreover, as the mode of action of tramadol does not overlap with that of NSAIDs, it is a useful agent to be combined with these drugs. Tramadol induces fewer opioid adverse reactions for a given level of analgesia compared with traditional opioids. Common adverse reactions of tramadol such as nausea and dizziness, which usually occur only at the beginning of therapy and attenuate over time, can be further minimized by up-titrating the drug over several days. Dose adjustment is only necessary in patients over 75 years of age, or in those with either hepatic or renal insufficiency. Tramadol should be avoided or used with caution in epileptics, or in individuals who are receiving seizure-threshold lowering drugs. Finally, tramadol has a low risk of abuse because it has only a weak opioid effect and its monoaminergic action could inhibit the development of dependence. The low abuse potential of tramadol has been demonstrated by postmarketing surveillance data.

Authors+Show Affiliations

Clinical Pharmacology & Multidisciplinary Pain Centre, University Hospital, Geneva, Switzerland.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

11310478

Citation

Desmeules, J A.. "The Tramadol Option." European Journal of Pain (London, England), vol. 4 Suppl A, 2000, pp. 15-21.
Desmeules JA. The tramadol option. Eur J Pain. 2000;4 Suppl A:15-21.
Desmeules, J. A. (2000). The tramadol option. European Journal of Pain (London, England), 4 Suppl A, 15-21.
Desmeules JA. The Tramadol Option. Eur J Pain. 2000;4 Suppl A:15-21. PubMed PMID: 11310478.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The tramadol option. A1 - Desmeules,J A, PY - 2001/4/20/pubmed PY - 2001/5/5/medline PY - 2001/4/20/entrez SP - 15 EP - 21 JF - European journal of pain (London, England) JO - Eur J Pain VL - 4 Suppl A N2 - Tramadol is an option for the treatment of rheumatological pain. Its mode of action and safety profile distinguishes it from other opioids. Tramadol differs from other opioids by combining a weak opioid and a monoaminergic mode of action. It is effective in different types of moderate-to-severe pain, including neuropathic pain. Moreover, as the mode of action of tramadol does not overlap with that of NSAIDs, it is a useful agent to be combined with these drugs. Tramadol induces fewer opioid adverse reactions for a given level of analgesia compared with traditional opioids. Common adverse reactions of tramadol such as nausea and dizziness, which usually occur only at the beginning of therapy and attenuate over time, can be further minimized by up-titrating the drug over several days. Dose adjustment is only necessary in patients over 75 years of age, or in those with either hepatic or renal insufficiency. Tramadol should be avoided or used with caution in epileptics, or in individuals who are receiving seizure-threshold lowering drugs. Finally, tramadol has a low risk of abuse because it has only a weak opioid effect and its monoaminergic action could inhibit the development of dependence. The low abuse potential of tramadol has been demonstrated by postmarketing surveillance data. SN - 1090-3801 UR - https://www.unboundmedicine.com/medline/citation/11310478/The_tramadol_option_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=1090-3801&date=2000&volume=4&issue=&spage=15 DB - PRIME DP - Unbound Medicine ER -